Literature DB >> 1730601

Mechanism of molecular recognition. Structural aspects of 3,3'-diiodo-L-thyronine binding to human serum transthyretin.

A Wojtczak1, J Luft, V Cody.   

Abstract

The three-dimensional structure of the thyroid hormone metabolite, 3,3'-diiodo-L-thyronine (3,3'-T2), complex with human serum transthyretin (TTR) has been refined to R = 18.5% for 8-2 A resolution data. This is the first detailed description of a thyroid hormone metabolite binding to a thyroid transport protein. The four TTR monomeric subunits form a tetramer in the same manner as the native transthyretin reported earlier (Blake, C. C. F., Geisow, M. J., Oatley, S. J., Rerat, B., and Rerat, C. (1978) J. Mol. Biol. 121, 339-356). The two hormone binding sites of the TTR tetramer are occupied by 3,3'-T2. A statistical disorder model for the ligand was applied with a 50% occupancy to account for the discrepancy between the crystallographic 2-fold symmetry of the binding sites and the lack of such symmetry for 3,3'-T2. The bound metabolite has an overall transoid conformation with the either bridge intermediate between skewed and perpendicular. The hormone metabolite is bound 3.5 A deeper and with a different orientation in the channel than observed for thyroxine (T4), thereby revealing the presence of another set of halogen binding sites close to the center of the tetramer. When compared with the binding of T4, these data show that the 3-iodine of 3,3'-T2 occupies the same site as the 3'-iodine of T4, and the metabolite 3'-iodine occupies the water site observed in the T4 complex. The binding affinity of 3,3'-T2, which is 100-fold lower than that of T4, reflects the lack of the second pair of iodine atoms interacting in the channel. In order to understand the tighter binding of T4 observed in the Ala-109----Thr mutant, modeling studies were carried out that indicate that this modification could shorten the contacts between thyroid hormone iodines and residues 108-110 of the binding site.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730601

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.

Authors:  Sungwook Choi; Natàlia Reixach; Stephen Connelly; Steven M Johnson; Ian A Wilson; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2010-02-03       Impact factor: 15.419

2.  A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.

Authors:  Sungwook Choi; Jeffery W Kelly
Journal:  Bioorg Med Chem       Date:  2010-12-30       Impact factor: 3.641

Review 3.  The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.

Authors:  Steven M Johnson; Stephen Connelly; Colleen Fearns; Evan T Powers; Jeffery W Kelly
Journal:  J Mol Biol       Date:  2012-01-05       Impact factor: 5.469

4.  Detection and characterization of aggregates, prefibrillar amyloidogenic oligomers, and protofibrils using fluorescence spectroscopy.

Authors:  Mikael Lindgren; Karin Sörgjerd; Per Hammarström
Journal:  Biophys J       Date:  2005-03-11       Impact factor: 4.033

5.  Crystal structure determination at 2.3-A resolution of human transthyretin-3',5'-dibromo-2',4,4',6-tetrahydroxyaurone complex.

Authors:  E Ciszak; V Cody; J R Luft
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

6.  Inhibiting transthyretin amyloid fibril formation via protein stabilization.

Authors:  G J Miroy; Z Lai; H A Lashuel; S A Peterson; C Strang; J W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

7.  The Effect of (-)-Epigallo-catechin-(3)-gallate on Amyloidogenic Proteins Suggests a Common Mechanism.

Authors:  Kathrin Andrich; Jan Bieschke
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

8.  Rigorous treatment of multispecies multimode ligand-receptor interactions in 3D-QSAR: CoMFA analysis of thyroxine analogs binding to transthyretin.

Authors:  Senthil Natesan; Tiansheng Wang; Viera Lukacova; Vladimir Bartus; Akash Khandelwal; Stefan Balaz
Journal:  J Chem Inf Model       Date:  2011-04-08       Impact factor: 4.956

9.  Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma.

Authors:  Sungwook Choi; Stephen Connelly; Natàlia Reixach; Ian A Wilson; Jeffery W Kelly
Journal:  Nat Chem Biol       Date:  2010-02       Impact factor: 15.040

10.  Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic carriers and structural analysis.

Authors:  M R Almeida; A M Damas; M C Lans; A Brouwer; M J Saraiva
Journal:  Endocrine       Date:  1997-06       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.